1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 5, 1997, Pages 1082-1093

  Daluge, Susan M ^a   Good, Steven S ^a   Faletto, Michael B ^a,c   Miller, Wayne H ^a   St Clair, Marty H ^a   Boone, Lawrence R ^a   Tisdale, Margaret ^b   Parry, Nigel R ^b   Reardon, John E ^a   Dornsife, Ronna E ^a   Averett, Devron R ^a,d   Krenitsky, Thomas A ^a,e  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^d Valeant Pharmaceuticals International   (United States)

^e Krenitsky Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CARBOCYCLIC NUCLEOSIDE; CARBOVIR; DIDANOSINE; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MIXTURE; DRUG PENETRATION; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0030982931     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.5.1082     Document Type: Article

References (71)

1. Averett, D. R. 1989. Anti-HIV compound assessment by two novel high capacity assays. J. Virol. Methods 23:263-276.
2. Brouwer, K. R., R. L. St. Claire, J. Lagarde, J. E. Patanella, J. S. Walsh, and G. T. Miwa. 1990. The pharmacokinetics of (-)-carbovir in rats: evidence for nonlinear elimination. Drug Metab. Dispos. 18:1078-1083.
3. Ching, S. V., K. M. Ayers, R. E. Dornsife, G. L. Grebe, and J. L. Howard. 1994. Nonclinical toxicology and in vitro toxicity studies with the novel anti-HIV agent (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89) succinate, abstr. I88, p. 92. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology, Washington, D.C.
4. Collins, J. M., R. W. Klecker, Jr., J. A. Kelley, J. S. Roth, C. L. McCully, F. M. Balis, and D. J. Poplack. 1988. Pyrimidine dideoxyribo-nucleosides: selectivity of penetration into cerebrospinal fluid. J. Pharmacol. Exp. Ther. 245:466-470.
5. Daluge, S. M. January 1990. European patent 349242.
6. Daluge, S. M. June 1991. European patent 434450.
7. Daluge, S. M. Unpublished data.
8. Daluge, S. M., S. S. Good, M. B. Faletto, M. T. Martin, W. H. Miller, D. R. Averett, M. H. St. Clair, L. R. Boone, M. Tisdale, and J. E. Reardon. 1995. 1592U89 succinate - a potent, selective anti-HIV carbocyclic nucleoside. Antiviral Res. 26:A228.
9. Daluge, S. M., S. S. Good, M. T. Martin, S. R. Tibbels, W. H. Miller, D. R. Averett, M. H. St. Clair, and K. M. Ayers. 1994. 1592U89 Succinate - a novel carbocyclic nucleoside analogue with potent, selective anti-HIV activity, abstr. I6, p. 7. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
10. Daluge, S. M., D. J. M. Purifoy, P. M. Savina, M. H. St. Clair, N. R. Parry, I. K. Dev, P. Novak, K. M. Ayers, J. E. Reardon, G. B. Roberts, J. A. Fyfe, M. R. Blum, D. R. Averett, R. E. Dornsife, B. A. Domin, R. Ferone, D. A. Lewis, and T. A. Krenitsky. 1994. 5-Chloro-2′,3′-dideoxy-3′-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob. Agents Chemother. 38:1590-1603.
11. Davis, M. G., and R. W. Jansen. 1994. Inhibition of hepatitis B virus in tissue culture by alpha interferon. Antimicrob. Agents Chemother. 38:2921-2924.
12. Dornsife, R. E., and D. R. Averett. 1996. In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans. Antimicrob. Agents Chemother. 40:514-519.
13. Dornsife, R. E., M. H. St. Clair, A. T. Huang, T. J. Panella, G. W. Koszalka, C. L. Burns, and D. R. Averett. 1991. Anti-human immunodeficiency virus synergism by zidovudine (3′-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. Antimicrob. Agents Chemother. 35:322-328.
14. Du, D. L., D. A. Volpe, C. K. Grieshaber, and M. J. Murphy, Jr. 1992. In vitro toxicity of 3′-azido-3′-deoxythymidine, carbovir and 2′,3′-didehydro-2′,3′-dideoxythymidine to human and murine haematopoietic progenitor cells. Br. J. Haematol. 80:437-445.
15. Faletto, M. B., W. H. Miller, E. P. Garvey, J. E. Reardon, and S. S. Good. 1994. Unique intracellular activation of a new anti-HIV agent (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89) in the human T-lymphoblastoid cell line CEM-T4, abstr. I84, p. 92. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
16. Faletto, M. B., W. H. Miller, E. P. Garvey, M. H. St. Clair, S. M. Daluge, and S. S. Good. 1997. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob. Agents Chemother. 41: 1099-1107.
17. Fischl, M. A., D. D. Richman, N. Hansen, A. C. Collier, et al. 1990. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type I (HIV) infection. Ann. Intern. Med. 112:727-737.
18. Gadler, H. 1983. Nucleic acid hybridization for measurement of effects of antiviral compounds on human cytolomegalovirus DNA replication. Antimicrob. Agents Chemother. 24:370-374.
19. Garrett, C., and D. V. Santi. 1979. A rapid and sensitive high pressure liquid chromatography assay for deoxyribonucleoside triphosphates in cell extracts. Anal. Biochem. 99:268-273.
20. Good, S. S., S. M. Daluge, S. V. Ching, K. M. Ayers, W. B. Mahony, M. B. Faletto, B. A. Domin, B. S. Owens, R. E. Dornsife, J. A. McDowell, S. W. LaFon, and W. T. Symonds. 1995. 1592U89 succinate - preclinical toxicological and disposition studies and preliminary clinical pharmacokinetics. Antiviral Res. 26:A229.
21. Good, S. S., B. S. Owens, M. B. Faletto, W. B. Mahony, and B. A. Domin. 1994. Disposition in monkeys and mice of (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89) succinate, a potent inhibitor of HIV, abstr. I86, p. 92. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
22. Ho, D. H. W., C. Pincus, C. J. Carter, R. S. Benjamin, E. J. Freireich, ana G. P. Bodey. 1980. Distribution and inhibition of adenosine deaminase in tissues of man, rat, and mouse. Cancer Treatment Rep. 64:629-633.
23. Ho, H.-T., and M. J. M. Hitchcock. 1989. Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob. Agents Chemother. 33:884-849.
24. Huang, S.-H., R. P. Remmel, and C. L. Zimmerman. 1991. The bioavailability and nonlinear clearance of (-)-carbovir in the rat. Pharm. Res. 8:739-743.
25. Hughes, W., J. McDowell, L. Adams, P. Flynn, S. Hetherington, M. Kline, J. Shenep, R. Yogev, and S. LaFon. 1996. Evaluation of the novel nucleoside 1592U89 in a phase I safety and pharmacokinetics (PK) study in HIV-infected infants and children, abstr. 195, p. 115. In Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections. Infectious Diseases Society of America for the foundation for Retrovirology and Human Health, Alexandria, Va.
26. Jansen, R. W., L. C. Johnson, and D. R. Averett. 1993. High-capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay. Antimicrob. Agents Chemother. 37:441-447.
27. Kavlick, M. F., T. Shirasaka, E. Kojima, J. M. Pluda, F. Hui, Jr., R. Yarchoan, and H. Mitsuya. 1995. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (-)-2′,3′-dideoxy-3′-thiacytidine. Antiviral Res. 28:133-146.
28. Koszalka, G. W., C. L. Burns, M. St. Clair, L. W. Frick, C. U. Lambe, M. T. Paff, D. J. Nelson, B. Korba, K. Ayers, and T. A. Krenitsky. 1995. Inhibition of HIV- and HBV-virus replication by 2,6-disubstituted purine 2′,3′-dideoxynucleosides. Antiviral Res. 26:A245.
29. Kurtzberg, J., and S. G. Carter. 1990. Differential toxicity of carbovir and AZT to human bone marrow hematopoietic progenitor cells in vitro. Exp. Hematol. 18:1094-1096.
30. Larder, B. A. 1995. Viral resistance and the selection of antiretroviral combinations. J. Acquired Immunodefic. Syndr. Hum. Retrovirol. 10(Suppl. 1): S28-S33.
31. Larder, B. A., B. Chesebro, and D. D. Richman. 1990. Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob. Agents Chemother. 34:436-441.
32. Mahony, W. B., B. A. Domin, S. M. Daluge, W. H. Miller, and T. P. Zimmerman. 1992. Enantiomeric selectivity of carbovir transport. J. Biol. Chem. 267:19792-19797.
33. + CEM cells. Proc. Am. Assoc. Cancer Res. 36:2211.
34. Mahony, W. B., B. A. Domin, K. L. Prus, and T. P. Zimmerman. Unpublished data.
35. Marr, C. L. P., and C. R. Penn. 1992. Stability of carbovir, a potent inhibitor of HIV, to phosphorolysis by human purine nucleoside phosphorylase. Antiviral Chem. Chemother. 3:121-124.
36. Martin, J. L., C. E. Brown, N. Matthews-Davis, and J. E. Reardon. 1994. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob. Agents Chemother. 38:1230-1238.
37. McDowell, J. A., W. T. Symonds, P. N. Kumar, D. E. Sweet, M. R. Blum, and S. W. LaFon. 1995. Initial phase-I study of anti-HIV agent 1592U89 in a single-dose escalation design including food effect and dosage form evaluation, abstr. I109, p. 224. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
38. Mellors, J. W., H. Bazmi, C. K. Chu, and R. F. Schinazi. 1996. K65R mutation in HIV-1 reverse transcriptase causes resistance to (-)-β-D-dioxolane-guanosine and reverses AZT resistance, abstr. 7. In 5th Workshop on HIV Drug Resistance. Antiviral Ther. 1(Suppl.1).
39. Merigan, T. C., and G. Skowron. 1990. Safety and tolerance of dideoxycytidine as a single agent. Am. J. Med. 88(Suppl. 5B):11S-15S.
40. Miller, W. M., S. M. Daluge, E. P. Garvey, S. Hopkins, J. E. Reardon, F. L. Boyd, and R. L. Miller. 1992. Phosphorylation of carbovir enantiomers by cellular enzymes determines the stereoselectivity of antiviral activity. J. Biol. Chem. 267:21220-21224.
41. Mitsuya, H., M. Matsukura, and S. Broder. 1987. Rapid in vitro systems for assessing activity of agents against HTLV-III/LAV, p. 309-321. In S. Broder (ed.), AIDS: modern concepts and therapeutic challenges. Marcel Dekker, New York, N.Y.
42. Parker, W. B., S. C. Shaddix, B. J. Bowdon, L. M. Rose, R. Vince, W. M. Shannon, and L. L. Bennett, Jr. 1993. Metabolism of carbovir, a potent inhibitor of human immunodeficiency virus type 1, and its effects on cellular metabolism. Antimicrob. Agents Chemother. 37:1004-1009.
43. Parker, W. B., E. L. White, S. C. Shaddix, L. J. Ross, R. W. Buckheit, Jr., J. M. Germany, J. A. Secrist III, R. Vince, and W. M. Shannon. 1991. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerases α, β, and γ by the 5′-triphosphates of carbovir, 3′-azido-3′-deoxythymidine, 2′,3′-dideoxyguanosine, and 3′-deoxythymidine. J. Biol. Chem. 266:1754-1762.
44. Petersen, E. A., C. H. Ramirez-Ronda, W. D. Hardy, R. Schwarz, H. S. Sacks, S. Follansbee, D. M. Peterson, A. Cross, R. E. Anderson, and L. M. Dunkle. 1995. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J. Infect. Dis. 171(Suppl. 2):S131-S139.
45. Pfleiderer, W. 1963. The solubility of heterocyclic compounds, p. 177-182. In A. R. Katritzky (ed.), Physical methods in heterocyclic chemistry, vol. 1. Academic Press, New York, N.Y.
46. Prichard, M. N., and C. Shipman, Jr. 1990. A three-dimensional model to analyze drug-drug interactions ("Macsynergy™"). Antiviral Res. 14:181-206.
47. Prus, K. L. (Glaxo Wellcome Inc., Research Triangle Park, N.C.). Personal communication.
48. Prus, K. L., D. R. Averett, and T. P. Zimmerman. 1990. Transport and metabolism of 9-β-D-arabinofuranosylguanine in a human T-lymphoblastoid cell line: nitrobenzylthioinosine-sensitive and -insensitive influx. Cancer Res. 50:1817-1821.
49. Reardon, J. E. 1992. Human immunodeficiency virus reverse transcriptase: steady-state and pre-steady-state kinetics of nucleotide incorporation. Biochemistry 31:4473-4479.
50. Reardon, J. E., E. S. Furfine, and N. Cheng. 1991. Human immunodeficiency virus reverse transcriptase substrate and inhibitor kinetics with thymidine 5′-triphosphate and 3′-azido-3′-deoxythymidine 5′-triphosphate. J. Biol. Chem. 266:14128-14134.
51. Remington, K. M., B. Cheseboro, K. Wehrly, N. C. Pedersen, and T. W. North. 1991. Mutants of feline immunodeficiency virus resistant to 3′-azido-3′-deoxythymidine. J. Virol. 65:308-312.
52. Richman, D. D., M. A. Fischl, M. H. Grieco, M. S. Gottlieb, P. A. Volberding, O. L. Laskin, J. M. Leedom, J. E. Groopman, D. Mildvan, M. S. Hirsh, G. G. Jackson, D. T. Durack, D. Phil, S. Nusinoff-Lehrman, and the AZT Collaborative Working Group. 1987. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 317:192-197.
53. Rocancourt, D., C. Bonnerot, H. Jouin, M. Emmerman, and J.-F. Nicolas. 1990. Activation of a β-galactosidase recombinant provirus: application to titration of human immunodeficiency virus (HIV) and HIV-infected cells. J. Virol. 64:2660-2668.
54. 3, abstr. 195, p. 89. In Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections. Infectious Diseases Society of America for the foundation for Retrovirology and Human Health, Alexandria, Va.
55. 3, abstr. Th.B.294, p. 225. In Abstracts of the XIth International Conference on AIDS, Vancouver, Canada.
56. Sherman, P. A., and J. A. Fyfe. 1989. Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. Anal. Biochem. 180:222-226.
57. Skowron, G. 1995. Biological effects and safety of stavudine: overview of phase I and II clinical trials. J. Infect. Dis. 171(Suppl. 2):S113-S117.
58. Spector, T., T. E. Jones, and L. M. Beacham III. 1983. Conversion of 2,6-diamino-9-(2-hydroxyethoxymethyl)purine to acyclovir as catalyzed by adenosine deaminase. Biochem. Pharmacol. 32:2505-2509.
59. St. Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
60. 6-alkylated adenine and adenosine analogs to mouse hepatoma cells. Exp. Cell Biol. 57:53-59.
61. Tisdale, M., T. Alnadaf, and D. Cousens. 1997. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob. Agents Chemother. 41:1094-1098.
62. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
63. Tisdale, M., N. R. Parry, D. Cousens, M. H. St. Clair, and L. R. Boone. 1994. Anti-HIV activity of (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89), abstr. I82, p. 92. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
64. Trennery, P. (Medicines Safety Evaluation, Glaxo Wellcome plc, Ware, United Kingdom). Personal communication.
65. Upton, R. A. 1975. Simple and reliable method for serial sampling of blood from rats. J. Pharm. Sci. 64:112-114.
66. Van Draanen, N. A., M. Tisdale, N. R. Parry, R. Jansen, R. E. Dornsife, J. V. Tuttle, D. R. Averett, and G. W. Koszalka. 1994. Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides. Antimicrob. Agents Chemother. 38:868-871.
67. Vince, R., M. Hua, J. Brownell, S. M. Daluge, F. C. Lee, W. M. Shannon, G. C. Lavelle, J. Qualls, O. S. Weislow, R. Kiser, P. G. Canonico, R. H. Schultz, V. L. Narayanan, J. G. Mayo, R. H. Shoemaker, and M. R. Boyd. 1988. Potent and selective activity of a new carbocyclic nucleoside analog (carbovir: NSC 614846) against human immunodeficiency virus in vitro. Biochem. Biophys. Res. Commun. 156:1046-1053.
68. Wainberg, M. A., H. Salomon, Z. Gu, J. S. Montaner, T. P. Cooley, R. McCaffrey, J. Ruedy, H. M. Hirst, N. Cammack, J. Cameron, et al. 1995. Development of HIV-1 resistance to (-)-2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS (Philadelphia) 9:351-357.
69. Walsh, J. S., J. E. Patanella, S. E. Unger, K. R. Brouwer, and G. T. Miwa. 1990. The metabolism and excretion of carbovir, a carbocyclic nucleoside, in the rat. Drug Metab. Dispos. 18:1084-1091.
70. Yarchoan, R., P. Brouwers, J. M. Pluda, K. M. Wyvill, R. V. Thomas, N. Hartman, H. Mitsuya, D. G. Johns, and S. Broder. 1990. Long-term toxicity/activity profile of 2′,3′-dideoxyinosine in AIDS or AIDS-related complex. Lancet 336:526-529.
71. Zimmerman, T. P., W. B. Mahony, and K. L. Prus. 1987. 3′-Azido-3′-deoxythymidine - an unusual analog that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J. Biol. Chem. 262:5748-5754.